SCHEMBL29565663

SCHEMBL29565663

Clc1ccc(NC2CC2)nn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
IL1B P01584 1/20 0.50
NLRP3 Q96P20 1/20 0.50
CNR2 P34972 1/20 0.45
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HCAR3 P49019 1/20 0.41
ACHE P22303 1/20 0.40
RAB9A P51151 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MALT1 Q9UDY8 1/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22655135 1.00 GAA (0.52) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL5644767 0.90 CNR2 (0.56) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL22214271 0.83 ALDH1A1 (0.44) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL17961755 0.82 ALDH1A1 (0.47) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL22655150 0.81 IL1B (0.50) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL22655018 0.81 IL1B (0.50) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL22655020 0.81 IL1B (0.50) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL17961795 0.81 ALDH1A1 (0.42) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL17961766 0.81 ALDH1A1 (0.42) GAAALDH1A1MAPTIL1BNLRP3
SCHEMBL17961764 0.81 ALDH1A1 (0.42) GAAALDH1A1MAPTIL1BNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2025-08-28 US disclosed
US-12139471-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2024-11-12 US disclosed
US-20220251067-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2022-08-11 US disclosed
US-11254653-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254653-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 GAA 3699/4885ALDH1A1 2869/4885MAPT 913/4885
US-20220251067-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 GAA 3699/4885ALDH1A1 2869/4885MAPT 913/4885
US-12139471-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 GAA 3699/4885ALDH1A1 2869/4885MAPT 913/4885
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 GAA 3699/4885ALDH1A1 2869/4885MAPT 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.